NCT01309490

Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients

An Open-label, Dose Escalation Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients Expressing Elevated eIF4E

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Jewish General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn whether oral Ribavirin is safe and effective in treating patients with solid tumour cancers, that have high levels of the protein eIF4E.

Detailed description

This is a dose escalating, open-label, Phase I/II study of single agent oral ribavirin administered daily in solid tumour cancer patients who have failed standard treatments, overexpress eIF4E, and have easily accessible disease for serial biopsies.

Conditions

• Malignant Solid Tumor

Interventions

Type	Name	Description
DRUG	Ribavirin	Dose Level: 1 1400 mg po BID Dose Level: 2 1800 mg po BID Dose Level: 3 2200 mg po BID Dose Level: 4 2600 mg po BID Dose Level: 5 3000 mg po BID

Timeline

• Start date: 2011-03-17
• Primary completion: 2014-10-29
• Completion: 2014-10-29
• First posted: 2011-03-07
• Last updated: 2025-07-29

Locations

1 site across 1 country: Canada